StockData
Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc. (ASMB) company profile

ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/309% below fair value
$22.50+1.21 (+5.68%)

Close on Nov 17, 2026Market cap $458.11MP/E –Yield –

About Assembly Biosciences

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biotechnology enterprise that develops novel therapeutic candidates targeting serious viral infections. Its pipeline comprises multiple investigational treatments, including helicase-primase inhibitors for recurrent genital herpes, an oral entry inhibitor for hepatitis delta virus, and a next-generation capsid assembly modulator for chronic hepatitis B. The company also develops an oral broad-spectrum non-nucleoside polymerase inhibitor for transplant-associated herpesviruses. Its target end users are patients suffering from severe, chronic, or recurrent viral illnesses, including immunocompromised individuals undergoing organ transplants.

The organization conducts clinical trials and research activities across multiple regions, with clinical trial filings, regulatory submissions, and study sites situated in the United States and European nations. The company also collaborates internationally with Gilead Sciences on licensing and late-stage development for select antiviral programs. The provided text contains no mention of the total number of physical operating facilities or the location of the corporate headquarters.

Summary of the business section of Assembly Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Assembly Biosciences, Inc.
Headquarters
South San Francisco, CA
Address
Two Tower Place, 7th Floor 94080
Phone
(833) 409-4583
Employees
73, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Jose, California

Stock & identifiers

Ticker
ASMB
Former tickers
VTUS until Aug 14, 2014
Exchange
Nasdaq
IPO date
Dec 17, 2010
Shares outstanding
20M, Aug 7, 2026
Public float
$97.80M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-12 reverse, Feb 12, 2024; 1-for-5 reverse, Jul 14, 2014
SEC CIK
1426800
CUSIP
045396108
ISIN
US0453961080
FIGI
BBG000R62Q06
Share class FIGI
BBG001T9BMW0
LEI
5299007Y1X8RBDFT8C40
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jason A. OkazakiCEO and President, Director195,532
Jeanette M. BjorkquistPFO and PAO17,673
William E. Delaney IVChief Scientific Officer74,035
Anuj GaggarChief Medical Officer53,800
Nicole S. WhiteChief Manufacturing Officer59,257
Susan MahonyDirector–
Lisa Johnson-PrattDirector–
Michael HoughtonDirector3,202
Anthony E. AltigDirector8,000
Gina ConsylmanDirector–
John G. McHutchisonDirector18,347
William R. RingoDirector17,465

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.48M$5.51M$1.26M$218–
FY2024$1.77M$2.15M$895.50K$101–
FY2023$1.37M$1.13M$758.67K$63–
FY2022$1.76M$1.32M$1.61M$21–
FY2021$2.87M$1.08M$1.15M$39–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jason A. Okazaki
Chief Executive Officer and President
$647.50K$661.67K$573.57K$585.00K$15.24K$2.48M+41%
William E. Delaney IV, Ph.D.
Chief Scientific Officer
$511.33K$236.27K$199.26K$302.80K$15.24K$1.26M+31%
Anuj Gaggar, M.D., Ph.D.
Chief Medical Officer
$502.86K$236.27K$189.10K$303.00K$14.81K$1.25M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 17, 2010
Offer price
$6.00
Securities offered
2,900,000
Gross proceeds
$17.40M
Exchange
Nasdaq
First trading day
Dec 17, 2010
First-day close
$6.30+5.0%
Lock-up ends (est.)
Jun 15, 2011

“The initial public offering price per share is $6.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 73 total employees and contracts with a number of temporary contractors, consultants and CROs.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 13, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 29, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 11, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 14, 2014Late filingNotification of late filing
Jul 14, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 11, 2014Name changeName changed from VENTRUS BIOSCIENCES INC to Assembly Biosciences, Inc.
Nov 13, 2012Late filingNotification of late filing
Nov 18, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 31, 2011Late filingNotification of late filing
Jan 20, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 17, 2010IPOInitial public offering priced (424B4 prospectus)
Dec 10, 2010ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?